FindTrial
Sign In

Rate of usage of drug dapagliflozin in Chronic kidney disease patients in clinic.

A prospective study on Dapagliflozin usage rate among CKD patients; insights from a tertiary clinic. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/04/066291
Enrollment
189
Registered
2024-04-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N189- Chronic kidney disease, unspecified

Interventions

Intervention1: NIL: NIL

Sponsors

Aisha Rania
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient diagnosed with CKD

Exclusion criteria

Exclusion criteria: Those with the advanced malignancy,Patients undergoing hemodialysis,Those who are diagnosed with psychiatric illness.Pregnant and lactating women.Patients with deafness or visual impairment.

Design outcomes

Primary

MeasureTime frame
The study results will give an overview of the use of dapagliflozin in CKD patients, Identification of barriers hindering their prescriptionTimepoint: at base line, 4weeks, 8 weeks—

Secondary

MeasureTime frame
Level of the medication knowledge among the patients undergoing treatment which helps in managing the health issues in these patients & as well as improve the treatment outcome. Identification & reporting adverse drug reactions will be useful in providing better treatment & thus enable rationalization of drug therapy. Timepoint: at base line, 4 weeks, 8 weeks—

Countries

India

Contacts

Public ContactThanveer Ahammed Chonar

Karavali College Of Pharmacy

thanveerahammed24@gmail.com8921269228

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026